All three efficacy end points met the prespecified noninferiority margin of 10 percentage points for oritavancin versus vancomycin : primary end point , 82.3 % versus 78.9 % ( 95 % confidence interval [ CI ] for the difference , -1.6 to 8.4 percentage points ) ; investigator-assessed clinical cure , 79.6 % versus 80.0 % ( 95 % CI for the difference , -5.5 to 4.7 percentage points ) ; and proportion of patients with a reduction in lesion area of 20 % or more , 86.9 % versus 82.9 % ( 95 % CI for the difference , -0.5 to 8.6 percentage points ) .